Latest revenue
$722.0K
as of 2025-09-30
Latest net income
$510.0K
as of 2025-09-30
Net margin
70.6%
as of 2025-09-30
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $6.2M
- Enterprise value
- $6.2M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $17.40
- 52-wk low
- $0.67
- Beta
- —
- Shares out
- 6.1M
5-year trend
What this company does
ENvue Medical sells a navigation-guided medical device system that helps clinicians safely insert feeding tubes into hospitalized patients needing enteral nutrition. Revenue comes from selling the FDA-cleared ENvue System hardware to U.S. hospitals alongside recurring sales of proprietary disposable feeding tubes and accessories. The company just transformed itself: formerly NanoVibronix, it merged with ENvue in February 2025, rebranded in December 2025, and executed two reverse stock splits this year while pushing early-stage commercialization.
Generated from FEED's filing dated 2026-04-15
Key risks
- Extreme dilution risk: two reverse splits in 2025 (1-for-11 in March, 1-for-10 in August), implying severe share price/financing pressure.
- Integration risk: February 2025 reverse-merger created two unrelated businesses (Israeli biofilm devices + US enteral feeding); company also rebranded December 2025.
- Early commercialization: ENvue System is in 'initial growth phase' with only 'multiple hospitals' engaged—revenue scale unproven against entrenched blind-insertion standard.
Generated from FEED's filing dated 2026-04-15
Profitability
Gross margin
6.0%
89.8%Operating margin
-896.6%
540.3%Net margin
-712.3%
391.8%Return on equity
-54.3%
41.6%Return on assets
-44.2%
56.7%Leverage
Debt / equity
0.23×
352.9%Debt / assets
18.5%
287.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | $312.0K | -29.7% | $-12.2M | -754.6% | -3919.6% |
Q3 2025 2025-09-30 | $722.0K | +92.0% | $510.0K | +151.1% | 70.6% |
Q2 2025 2025-06-30 | $494.0K | -39.5% | $-4.0M | -477.2% | -803.8% |
Q1 2025 2025-03-31 | $1.0M | +11.3% | $-2.5M | -324.3% | -243.4% |
Q4 2024 2024-12-31 | $444.0K | — | $-1.4M | — | -322.3% |
Q3 2024 2024-09-30 | $376.0K | -17.9% | $-998.0K | -37.3% | -265.4% |
Q2 2024 2024-06-30 | $817.0K | +177.9% | $-688.0K | +35.9% | -84.2% |
Q1 2024 2024-03-31 | $921.0K | — | $-588.0K | — | -63.8% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Orthopedic, Prosthetic & Surgical Appliances & Supplies · SIC 3842
Your notes
Keep private notes on FEED — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$640.8K
Insider selling
$0
Net activity
+$640.8K
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| 2026-01-14 | Christian Michael Glibert 10%+ owner | Purchase | 240,000 | $2.67 | $640.8K |
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns FEED
Institutional value
$38.6K
Total shares held
20.4K
Distinct holders
7
+1 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | 10.0K | $20.7K | — | New |
| 2 | Poehling Capital Management, INC. | 10.0K | $17.0K | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 189 | $450 | — | New |
| 4 | VANGUARD FIDUCIARY TRUST CO | 85 | $202 | — | New |
| 5 | WELLS FARGO & COMPANY/MN | 45 | $107 | — | New |
| 6 | UBS Group AG | 24 | $57 | -36 (-60.0%) | Trimmed |
| 7 | SBI Securities Co., Ltd. | 15 | $36 | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
- 1
Two reverse splits in five months (1-for-11, then 1-for-10) suggest listing-compliance distress—what's your current cash runway and Nasdaq bid-price status?
- 2
Five years post-launch, ENvue System is still 'initial growth phase'—how many hospitals are actively reordering disposables, and what's attach-rate per system?
- 3
The Series X Preferred and 12,526 Pre-Funded Warrants imply massive overhang beyond the 4.9% Exchange Cap—what's fully-diluted share count post-conversion?
Refreshed when FEED files a new report · last from 2026-04-15